Open-Angle Glaucoma (OAG) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Open-Angle Glaucoma (OAG) Market Outlook
Thelansis’s “Open-Angle Glaucoma (OAG)
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2024 To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Open-Angle Glaucoma (OAG) treatment
modalities options for eight major markets (USA, Germany, France, Italy, Spain,
UK, Japan, and China).
Open-Angle Glaucoma (OAG) Overview
Open-angle
glaucoma is a progressive optic neuropathy characterized by the acquired loss
of retinal ganglion cells and atrophy of the optic nerve. It constitutes over
90 percent of glaucoma cases in the United States. Elevated intraocular
pressure stands as a major risk factor, though it is not a diagnostic
criterion. Patients with elevated intraocular pressure have an approximately 1
percent per year risk of developing glaucomatous optic nerve damage. The
pathophysiology involves a progressive reduction in the number of retinal
ganglion cells, resulting from the pinching and death of nerve fibers at the
point where the optic nerve exits the eye. This process leads to thinning of
the neural rim and progressive enlargement of the optic nerve cup, causing a permanently
decreased visual field. The only known causative risk factors for open-angle
glaucoma are elevated intraocular pressure and insults to the eye, including
uveitis, trauma, and steroid therapy. Although steroid therapy may contribute
to elevated intraocular pressure, topical eye and periocular steroids are most
likely to increase pressure.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment